This clinical trial investigates the efficacy of fulvestrant compared to anastrozole and tamoxifen in postmenopausal women with invasive lobular breast cancer (ILC), a subtype that has been historically underrepresented in clinical studies. The trial's focus on identifying biomarkers of endocrine response and resistance could lead to more personalized treatment approaches, potentially capturing a significant share of the breast cancer market, which is projected to grow as precision medicine becomes more prevalent. The results may provide a competitive edge for fulvestrant in the treatment of ILC, particularly if it demonstrates superior efficacy or safety profiles compared to existing therapies. Given the increasing emphasis on targeted therapies, successful outcomes could enhance the market positioning of the sponsor and attract interest from pharmaceutical partners or investors.